Attached files

file filename
8-K - FORM 8-K - ALBEMARLE CORPd286470d8k.htm

Exhibit 99.1

 

   Contact:   
LOGO    Lorin Crenshaw            225.388.7322

Albemarle Reports Record Fourth Quarter and Record Full Year 2011 Results

 

 

BATON ROUGE, LA - January 23, 2012 –

Fourth quarter 2011 highlights:

 

 

Best fourth quarter earnings performance in Company history.

 

 

Quarterly earnings of $1.11 per share, up 21 percent over fourth quarter 2010 results.

 

 

Ninth consecutive quarter of year-over-year quarterly earnings growth for the Company.

 

 

Net sales of $707 million for the quarter, up 17 percent over fourth quarter 2010.

 

 

Full year 2011 finishes with highest annual revenue and earnings in history of the Company.

 

     Three Months Ended
December 31,
     Year Ended
December 31,
 

In thousands, except per share amounts

   2011      2010      2011      2010  

Net sales

   $ 707,390       $ 604,975       $ 2,869,005       $ 2,362,764   

Segment income

   $ 162,799       $ 135,842       $ 700,990       $ 519,182   

Net income attributable to Albemarle Corporation

   $ 99,443       $ 84,972       $ 436,280       $ 323,720   

Diluted earnings per share

   $ 1.11       $ 0.92       $ 4.77       $ 3.51   

Special item per share

   $ —         $ —         $ —         $ 0.05   
  

 

 

    

 

 

    

 

 

    

 

 

 

Diluted earnings per share excluding special item

   $ 1.11       $ 0.92       $ 4.77       $ 3.56   
  

 

 

    

 

 

    

 

 

    

 

 

 

Albemarle Corporation (NYSE: ALB) reported fourth quarter 2011 earnings of $99.4 million, or $1.11 per share, compared to fourth quarter 2010 earnings of $85.0 million, or $0.92 per share. The Company reported net sales of $707.4 million in the fourth quarter of 2011 compared to net sales of $605.0 million in the fourth quarter of 2010.

Earnings for the full year 2011 were $436.3 million, or $4.77 per share, compared to $323.7 million, or $3.51 per share, for 2010. Excluding the $7.0 million ($4.6 million after tax, or 5 cents per share) charge for restructuring costs in the first quarter of 2010, earnings for 2010 were $328.3 million, or $3.56 per share. Net sales for 2011 were $2.9 billion compared to $2.4 billion for 2010.

“We are very pleased to report strong fourth quarter results which capped a record year at Albemarle during which each of our business segments recorded the highest revenue and profitability in our history,” said Luke Kissam, President and CEO. “Despite a challenging operating environment in the second half of the year, we grew revenue by 21% to $2.9 billion and earnings by 34% to $4.77 per share. We closed the year with a very strong balance sheet, which gives us the financial flexibility to fund growth opportunities. These results, which are a credit to the strength of our businesses and the innovation of our employees, put us on track to achieve our Vision 2015 goals.”

 

1


Quarterly Segment Results

Catalysts generated net sales of $289.5 million in the fourth quarter of 2011, a 25 percent increase over net sales in the fourth quarter of 2010, due mainly to favorable pricing. Catalysts segment income was $83.6 million in the fourth quarter of 2011, up 43 percent over fourth quarter 2010 results of $58.5 million due primarily to favorable pricing gains while partly offset mainly by higher input costs and lower equity income versus the fourth quarter of 2010.

Polymer Solutions delivered net sales of $209.3 million in the fourth quarter of 2011, a 5 percent decrease over net sales in the fourth quarter of 2010, with favorable impacts from pricing and foreign currency being offset overall by lower volumes. Segment income for Polymer Solutions was $36.6 million in the fourth quarter of 2011, a 28 percent decline from $51.0 million in the fourth quarter of 2010, due primarily to lower volumes and higher input costs, partly offset by favorable pricing.

Fine Chemistry net sales in the fourth quarter of 2011 were $208.5 million, a 36 percent increase over net sales in the fourth quarter of 2010, due mainly to favorable volumes and pricing. Segment income for Fine Chemistry was $42.6 million for the fourth quarter of 2011, over 60 percent higher than fourth quarter 2010 results of $26.3 million, due primarily to favorable pricing and volume performance, partly offset by higher input costs and higher charges attributable to noncontrolling interests.

Corporate and Other

Corporate and other expense for the fourth quarter and year ended December 31, 2011 was $24.6 million and $97.5 million, respectively. The increase over the comparable periods in 2010 was due primarily to higher personnel-related costs including performance-based incentive compensation and pension costs.

Interest and financing expenses were $9.0 million for the fourth quarter of 2011 compared to $7.5 million for the fourth quarter of 2010, with this increase due primarily to higher average interest rates on outstanding borrowings during the 2011 period.

Our fourth quarter and full year 2011 effective income tax rates were 23.3 percent and 23.6 percent, respectively. Our effective tax rate continues to be influenced by the level and geographic mix of income and benefits from a favorable mix of income in lower tax jurisdictions.

 

2


Cash Flow

Our cash flow from operations was approximately $490 million for the full year 2011, and we had $469.4 million in cash and cash equivalents at December 31, 2011. During 2011, cash on hand and cash provided by operations funded capital expenditures for plant, machinery and equipment of approximately $198.0 million (which includes approximately $40.0 million in capital expenditures associated with our Jordan Bromine joint venture), long-term debt repayments of $109.6 million, pension and postretirement contributions of $59.8 million, dividends to shareholders of $57.8 million and repurchases of $178.1 million of our common stock.

Outlook

In the second half of 2011, the global economic uncertainty contributed to conservative cash management and lower demand in certain supply chains, and this was particularly true in our Polymer Solutions segment. How long that uncertainty will last is not clear at this time. However, our businesses remain healthy, and we believe the end markets we serve may stabilize or accelerate in the second half of 2012.

Earnings Call

The Company’s performance for the fourth quarter and the year ended December 31, 2011 will be discussed on a conference call at 8:00 AM Eastern Standard time on January 24, 2012. The call can be accessed by dialing 800-901-5217 (International Dial In # 617-786-2964), and entering conference ID 62911660. The Company’s earnings presentation and supporting material can be accessed through Albemarle’s website under Investors at www.albemarle.com.

About Albemarle

Albemarle Corporation, headquartered in Baton Rouge, Louisiana, is a leading global developer, manufacturer and marketer of highly-engineered specialty chemicals for consumer electronics, petroleum refining, utilities, packaging, construction, automotive/transportation, pharmaceuticals, crop protection, food-safety and custom chemistry services. Albemarle is committed to global sustainability and is continuing to advance its eco-practices and solutions in its three business segments, Polymer Solutions, Catalysts and Fine Chemistry, with Corporate Responsibility Magazine naming Albemarle among its prestigious “100 Best Corporate Citizens” list for 2011. Albemarle employs approximately 4,000 people and serves customers in approximately 100 countries. Albemarle regularly posts information to www.albemarle.com, including notification of events, news, financial performance, investor presentations and webcasts, Regulation G reconciliations, SEC filings and other information regarding the Company, its businesses and markets served.

Forward-Looking Statements

Some of the information presented in this press release, including, without limitation, statements with respect to product development, improvements in productivity, market trends, price and mix changes, expected growth, outlook and all other information relating to matters that are not historical facts may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. There can be no

 

3


assurance that actual results will not differ materially. Factors that could cause actual results to differ from expectations include, without limitation: changes in economic and business conditions; changes in financial and operating performance of our major customers and industries and markets served by us; the timing of orders received from customers; the gain or loss of significant customers; competition from other manufacturers; changes in the demand for our products; limitations or prohibitions on the manufacture and sale of our products; availability of raw materials; changes in the cost of raw materials and energy and in our ability to pass through increases; acquisitions and divestitures, and changes in performance of acquired companies; fluctuations in foreign currencies; changes in laws and government regulation of our operations or our products; the occurrence of claims or litigation; the occurrence of natural disasters; the inability to maintain current levels of product or premises liability insurance or the denial of such coverage; political unrest, including terrorism or hostilities; political instability affecting our manufacturing operations or joint ventures; changes in accounting standards; the inability to achieve results from our global manufacturing cost reduction initiatives as well as our ongoing continuous improvement and rationalization programs; changes in the jurisdictional mix of our earnings; changes in monetary policies or inflation or interest rates, which may impact our ability to raise capital or increase our cost of funds, the performance of our pension fund investments and our pension expense and funding obligations; volatility and substantial uncertainties in the debt and equity markets; technology or intellectual property infringement and other risks; decisions we may make in the future; and the other factors detailed from time to time in the reports we file with the SEC, including those described under “Risk Factors” in our Annual Report on Form 10-K and our 2011 Quarterly Reports on Form 10-Q.

 

4


Albemarle Corporation and Subsidiaries

Consolidated Statements of Income

(In Thousands Except Per Share Amounts) (Unaudited)

 

     Three Months Ended
December 31,
    Year Ended
December 31,
 
     2011     2010     2011     2010  

Net sales

   $ 707,390      $ 604,975      $ 2,869,005      $ 2,362,764   

Cost of goods sold

     473,308        408,514        1,891,946        1,616,842   
  

 

 

   

 

 

   

 

 

   

 

 

 

Gross profit

     234,082        196,461        977,059        745,922   

Selling, general and administrative expenses

     79,021        70,403        312,136        265,722   

Research and development expenses

     18,987        14,672        77,083        58,394   

Restructuring and other charges (a)

     —          —          —          6,958   
  

 

 

   

 

 

   

 

 

   

 

 

 

Operating profit

     136,074        111,386        587,840        414,848   

Interest and financing expenses

     (8,998     (7,474     (37,574     (25,533

Other (expenses) income, net

     (177     1,204        357        2,788   
  

 

 

   

 

 

   

 

 

   

 

 

 

Income before income taxes and equity in net income of unconsolidated investments

     126,899        105,116        550,623        392,103   

Income tax expense

     29,591        23,802        130,014        92,719   
  

 

 

   

 

 

   

 

 

   

 

 

 

Income before equity in net income of unconsolidated investments

     97,308        81,314        420,609        299,384   

Equity in net income of unconsolidated investments (net of tax)

     6,636        8,025        43,754        37,975   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income

     103,944        89,339        464,363        337,359   

Net income attributable to noncontrolling interests

     (4,501     (4,367     (28,083     (13,639
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to Albemarle Corporation

   $ 99,443      $ 84,972      $ 436,280      $ 323,720   
  

 

 

   

 

 

   

 

 

   

 

 

 

Basic earnings per share

   $ 1.12      $ 0.93      $ 4.82      $ 3.54   

Diluted earnings per share

   $ 1.11      $ 0.92      $ 4.77      $ 3.51   

Weighted-average common shares outstanding – basic

     88,805        91,567        90,522        91,393   

Weighted-average common shares outstanding – diluted

     89,819        92,350        91,522        92,184   

See accompanying notes to the condensed consolidated financial information.

 

5


Albemarle Corporation and Subsidiaries

Condensed Consolidated Balance Sheets

(In Thousands) (Unaudited)

 

     December 31,
2011
     December 31,
2010
 

ASSETS

     

Cash and cash equivalents

   $ 469,416       $ 529,650   

Other current assets

     886,204         818,548   
  

 

 

    

 

 

 

Total current assets

     1,355,620         1,348,198   
  

 

 

    

 

 

 

Property, plant and equipment

     2,619,428         2,440,178   

Less accumulated depreciation and amortization

     1,489,948         1,433,865   
  

 

 

    

 

 

 

Net property, plant and equipment

     1,129,480         1,006,313   

Other assets and intangibles

     718,724         713,570   
  

 

 

    

 

 

 

Total assets

   $ 3,203,824       $ 3,068,081   
  

 

 

    

 

 

 

LIABILITIES AND EQUITY

     

Current portion of long-term debt

   $ 14,416       $ 8,983   

Other current liabilities

     386,762         355,194   
  

 

 

    

 

 

 

Total current liabilities

     401,178         364,177   
  

 

 

    

 

 

 

Long-term debt

     749,257         851,927   

Other noncurrent liabilities

     296,659         266,661   

Deferred income taxes

     77,903         109,570   

Albemarle Corporation shareholders’ equity

     1,591,277         1,416,074   

Noncontrolling interests

     87,550         59,672   
  

 

 

    

 

 

 

Total liabilities & equity

   $ 3,203,824       $ 3,068,081   
  

 

 

    

 

 

 

See accompanying notes to the condensed consolidated financial information.

 

6


Albemarle Corporation and Subsidiaries

Selected Consolidated Cash Flow Data

(In Thousands) (Unaudited)

 

     Year Ended December 31,  
     2011     2010  

Cash and cash equivalents at beginning of year

   $ 529,650      $ 308,791   

Cash and cash equivalents at end of year

   $ 469,416      $ 529,650   

Sources of cash and cash equivalents:

    

Net income

     464,363        337,359   

Proceeds from issuance of senior notes

     —          346,853   

Proceeds from other borrowings

     9,415        125,797   

Proceeds from exercise of stock options

     2,230        7,135   

Uses of cash and cash equivalents:

    

Capital expenditures

     (197,746     (75,478

Repurchases of common stock

     (178,132     (14,945

Repayments of long-term debt

     (109,591     (424,123

Dividends paid to shareholders

     (57,759     (49,643

Pension and postretirement contributions

     (59,773     (80,105

Cash impact from deconsolidation of Stannica JV, net

     —          (12,649

Investments in equity and other corporate investments

     (10,868     (1,338

Non-cash items:

    

Depreciation and amortization

     96,753        95,578   

Restructuring and other charges (a)

     —          6,958   

Equity in net income of unconsolidated investments

     (43,754     (37,975

See accompanying notes to the condensed consolidated financial information.

 

7


Albemarle Corporation and Subsidiaries

Consolidated Summary of Segment Results

(In Thousands) (Unaudited)

 

     Three Months Ended
December 31,
    Year Ended
December 31,
 
     2011     2010     2011     2010  

Net sales:

        

Polymer Solutions

   $ 209,318      $ 219,956      $ 1,001,922      $ 903,745   

Catalysts

     289,524        231,569        1,116,863        890,007   

Fine Chemistry

     208,548        153,450        750,220        569,012   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total net sales

   $ 707,390      $ 604,975      $ 2,869,005      $ 2,362,764   
  

 

 

   

 

 

   

 

 

   

 

 

 

Segment operating profit:

        

Polymer Solutions

   $ 36,018      $ 50,488      $ 239,918      $ 195,681   

Catalysts

     78,091        52,069        287,342        219,125   

Fine Chemistry

     46,497        29,254        157,884        79,505   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total segment operating profit

     160,606        131,811        685,144        494,311   
  

 

 

   

 

 

   

 

 

   

 

 

 

Equity in net income of unconsolidated investments:

        

Polymer Solutions

     1,200        1,875        7,696        8,734   

Catalysts

     5,463        6,475        36,259        29,648   

Fine Chemistry

     —          —          —          —     

Corporate & other

     (27     (325     (201     (407
  

 

 

   

 

 

   

 

 

   

 

 

 

Total equity in net income of unconsolidated investments

     6,636        8,025        43,754        37,975   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to noncontrolling interests:

        

Polymer Solutions

     (603     (1,405     (9,803     (6,154

Catalysts

     —          —          —          —     

Fine Chemistry

     (3,867     (2,914     (18,306     (7,357

Corporate & other

     (31     (48     26        (128
  

 

 

   

 

 

   

 

 

   

 

 

 

Total net income attributable to noncontrolling interests

     (4,501     (4,367     (28,083     (13,639
  

 

 

   

 

 

   

 

 

   

 

 

 

Segment income:

        

Polymer Solutions

     36,615        50,958        237,811        198,261   

Catalysts

     83,554        58,544        323,601        248,773   

Fine Chemistry

     42,630        26,340        139,578        72,148   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total segment income

     162,799        135,842        700,990        519,182   

Corporate & other

     (24,590     (20,798     (97,479     (73,040

Restructuring and other charges (a)

     —          —          —          (6,958

Interest and financing expenses

     (8,998     (7,474     (37,574     (25,533

Other (expenses) income, net

     (177     1,204        357        2,788   

Income tax expense

     (29,591     (23,802     (130,014     (92,719
  

 

 

   

 

 

   

 

 

   

 

 

 

Net income attributable to Albemarle Corporation

   $ 99,443      $ 84,972      $ 436,280      $ 323,720   
  

 

 

   

 

 

   

 

 

   

 

 

 

See accompanying notes to the condensed consolidated financial information.

 

8


Notes to the Condensed Consolidated Financial Information

 

(a) The year ended December 31, 2010 included charges amounting to $7.0 million ($4.6 million after income taxes, or 5 cents per share) that related principally to reductions in force at our Bergheim, Germany site.

Additional Information

It should be noted that earnings, earnings per share and effective income tax rates which exclude special items, as well as presentations of segment operating profit, segment income, EBITDA, EBITDA excluding special items, EBITDA margin and EBITDA margin excluding special items are financial measures that are not required by, or presented in accordance with, accounting principles generally accepted in the United States, or GAAP. These measures are presented here to provide additional useful measurements to review our operations, provide transparency to investors and enable period-to-period comparability of financial performance.

A description of other non-GAAP financial measures that we use to evaluate our operations and financial performance, and reconciliation of these non-GAAP financial measures to the most directly comparable financial measures calculated and reported in accordance with GAAP, can be found in the Investors section of our website at www.albemarle.com, under “Non-GAAP Reconciliations” under “Financials.” Also, see attached for a supplemental reconciliation of our segment operating profit and segment income amounts to GAAP Operating profit and GAAP Net income attributable to Albemarle Corporation, respectively, as well as for a supplemental reconciliation of our GAAP Net income attributable to Albemarle Corporation to EBITDA and EBITDA excluding special items.

 

9


ALBEMARLE CORPORATION AND SUBSIDIARIES

Non-GAAP Reconciliation

(In Thousands)

(Unaudited)

Our segment information includes measures we refer to as “segment operating profit,” “segment income,” “EBITDA” and “EBITDA excluding special items,” which are financial measures that are not required by, or presented in accordance with, GAAP. The Company has reported segment operating profit, segment income, EBITDA and EBITDA excluding special items because management believes that these financial measures provide transparency to investors and enable period-to-period comparability of financial performance. Segment operating profit, segment income, EBITDA and EBITDA excluding special items should not be considered as alternatives to operating profit or net income attributable to Albemarle Corporation, as determined in accordance with GAAP.

See below for a reconciliation of segment operating profit and segment income, the non-GAAP financial measures, to operating profit and net income attributable to Albemarle Corporation, respectively, the most directly comparable financial measures calculated and reported in accordance with GAAP.

 

     Three Months Ended
December 31,
    Year Ended
December 31,
 
     2011     2010     2011     2010  

Total segment operating profit

   $ 160,606      $ 131,811      $ 685,144      $ 494,311   

Corporate & other *

     (24,532     (20,425     (97,304     (72,505

Restructuring and other charges

     —          —          —          (6,958
  

 

 

   

 

 

   

 

 

   

 

 

 

GAAP Operating profit

   $ 136,074      $ 111,386      $ 587,840      $ 414,848   
  

 

 

   

 

 

   

 

 

   

 

 

 

Total segment income

   $ 162,799      $ 135,842      $ 700,990      $ 519,182   

Corporate & other

     (24,590     (20,798     (97,479     (73,040

Restructuring and other charges

     —          —          —          (6,958

Interest and financing expenses

     (8,998     (7,474     (37,574     (25,533

Other (expenses) income, net

     (177     1,204        357        2,788   

Income tax expense

     (29,591     (23,802     (130,014     (92,719
  

 

 

   

 

 

   

 

 

   

 

 

 

GAAP Net income attributable to Albemarle Corporation

   $ 99,443      $ 84,972      $ 436,280      $ 323,720   
  

 

 

   

 

 

   

 

 

   

 

 

 

 

* Excludes corporate equity income and noncontrolling interest adjustments of $(58) and $(373) for the three-month periods ended December 31, 2011 and 2010, respectively, and $(175) and $(535) for the years ended December 31, 2011 and 2010, respectively.

 

10


See below for a reconciliation of EBITDA and EBITDA excluding special items, the non-GAAP financial measures, from net income attributable to Albemarle Corporation, the most directly comparable financial measure calculated and reported in accordance with GAAP. EBITDA is defined as Net income attributable to Albemarle Corporation before interest and financing expenses, income taxes, depreciation and amortization. EBITDA excluding special items is defined as EBITDA before the special item as listed below.

 

     Three Months Ended
December 31,
    Year Ended
December 31,
 
     2011     2010     2011     2010  

Net income attributable to Albemarle Corporation

   $ 99,443      $ 84,972      $ 436,280      $ 323,720   
  

 

 

   

 

 

   

 

 

   

 

 

 

Add:

        

Interest and financing expenses

     8,998        7,474        37,574        25,533   

Income tax expense

     29,591        23,802        130,014        92,719   

Depreciation and amortization

     24,827        24,092        96,753        95,578   
  

 

 

   

 

 

   

 

 

   

 

 

 

EBITDA

     162,859        140,340        700,621        537,550   

Restructuring and other charges

     —          —          —          6,958   
  

 

 

   

 

 

   

 

 

   

 

 

 

EBITDA excluding special item

   $ 162,859      $ 140,340      $ 700,621      $ 544,508   
  

 

 

   

 

 

   

 

 

   

 

 

 

Net sales

   $ 707,390      $ 604,975      $ 2,869,005      $ 2,362,764   
  

 

 

   

 

 

   

 

 

   

 

 

 

EBITDA Margin

     23.0     23.2     24.4     22.8
  

 

 

   

 

 

   

 

 

   

 

 

 

EBITDA Margin excluding special item

     23.0     23.2     24.4     23.0
  

 

 

   

 

 

   

 

 

   

 

 

 

 

11